Clinical Trial Update: A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

View source ↗

Summary

Pfizer conducted a study of novel hormonal therapies for metastatic castration-sensitive prostate cancer that has completed, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Novel Hormonal Therapies (NHTs)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Neoplasms | Status: COMPLETED | Results posted: 2025-06-04